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“Lack of consistency in calculating
patient-level daily MME has always
been a headache for me as an analyst




but may not provide enough detail
 behind the measure for the clinicians.”
Yanning Wang
14 US states impose limits on opioid dose,
ranging from 30 mg to 120 mg daily maximum.
So do many third-party payers. Despite being
enshrined in law, there is no standard way to
calculate daily MME. Therefore, we reviewed
the clinical guidelines, mobile apps, and literature
to identify and quantify the impact of denominator
dependency due to denitional variants.
Papers cited in the CDC Guideline use 4 different denitions, calling into
question the consistency of the evidence base on dose-related opioid harms. 
“Something that matters a lot to me is that equations can help
a researcher identify the concept they want to measure,
and then measure it.
And since each concept or formula has a very different
relationship to the common 90 MME/day threshold,
these equations clarify how we should be more nuanced




All-payer dispensing (PDMP) data from California and Florida
All adult residents
July through September 2018
Drugs Included
+ Outpatient prescriptions for solid oral opioid analgesics
+ Excludes buprenorphine
+ “High dose” dened as greater than 90 daily MME
+ Uniform conversion factors (CDC)
Statistical Analyses
1: Number of “high dose” patients compared between CA and FL
2: mg difference by patient between CA and FL
3: Meta-analysis with xed-effects inverse variance model using
    Higgins and Thompson’s I2 and X2 to assess heterogeneity
4: Sensitivity analysis at the 90.0-90.9 thereshold boundary
Sample Size
9,436,640 opioid analgesic prescriptions
California n=5,677,277
Florida n=3,759,363
3,916,461 unique adult residents
California n=2,430,870
Florida n=1,485,591 
Baseline 3-month Opioid Dispensing Rate Difference
California:     7.9 per 100 adult residents
Florida:         8.7 per 100 adult residents
In surveillance or policy evaluation, we may want to compare how many
 “high dose” patients are in one state versus another. We conducted a
meta analysis to determine if 4 studies using the same data would
return statistically consistent results. The only source of variation









































The 4 denitions yielded a 3-fold range of average daily MME:


























+mg more in FL
daily MME denition
How to read this graph
D1: Total Days Supply
D2: On-therapy Days
D3: Fixed Observation Window
D4: Maximum Daily Dose
July-September 2018
Only source of variation
comes from choice of
denition and 
metrics for daily MME
n=9,436,640 opioid Rx
n=3,916,461 patients
The 4 denitions could not agree how many more “high dose” 
patients there were in Florida compared to California, or average dose. 
Analysts could legitimately claim that FL had from 0.9mg to 13mg
more daily MME. Strong mean-median divergence was observed.
How does intepretation change based on the metric?
“It is disheartening, but unfortunately not surprising.
Far too often, we are victims of the good intentions of
those wanting to ‘do something’ about the opioid overdose epidemic,
but the something that is done oversimplifies the problem and
pushes cookbook medicine upon those of us with complicated
medical situations.
And while everyone debates whether the MME limit was
the right thing to do, we are forced to live by it,
because medical personnel and others treat guidelines as mandates.
So we wait. And we suffer.
And we hope it will all get sorted so we can get the care we need.”
Liz Joniak-Grant
Patient Pespective: So we wait. And we suffer.
Sensitivity Analysis
“The difference between including 90 MME
and excluding the category boundary
(≥90 vs. >90 mg) was unexpectedly huge.
The inclusion of the 90 daily MME cut
point could potentially introduce
misclassification especially when studies





• Assumed all medications taken as described
• Did not consider other sources, pharmaceutical or unregulated
• Did not differentiate cancer from non-cancer pain
• Did not consider atypical mu-opioid receptor agonism for
    respiratory depression (e.g., tapentadol, buprenorphine)
• Did not consider pharmacist-based days supply variation
• Did not consider social determinants of opioid prescribing
Conclusions
“Payers and lawmakers have grasped on to MME to guide policy decisions. While payers insist
they are not dictating care because the patient can still pay out-of-pocket for the
medication (I have many who do), for most patients this is not financially feasible.
As scientists, we often feel uncomfortable without objective data. While pain scores
and MME give us numbers by which judgments are being made, they do not begin to tell
the full story of the patient's pain condition. Because of this, the management of
pain truly typifies the art of medicine.”
Brooke Chidgey, Pain Management Physician
Clinical Pespective: The Art of Medicine
Chris Delcher
“It is clear that some patient experiences
with prescription drug monitoring
programs are negative.
This work is an example of how we can
put PDMP data to work positively
for an issue so critical to patient care. 
Because our study was conducted
in partnership with state PDMPs,
we had an opportunity to educate
them on the impact of these important
measures.”
Toska Cooper
“There’s no one size fits all approach
here. It's not practical to have a
universal MME formula when many
factors go into patient care.
But what we can do is make all the
calculations and code visible. 
Regardless of the audience, 
from clinical practice to legislation,
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Proportion of  “High Dose” Patients by Denition and State
"The computational ease and the evocative lure of molecular
fundamentals collide in an optimal level of cognitive
complexity to engender MMEs with an unsubstantiated
aura of immutability.
Our analysis revealed definitional inconsistencies that have
been overlooked. There are implications for clinical care,
policy, and epidemiology, and the potential to capriciously
impact many thousands of patients."
Dasgupta N, Wang Y, Bae J, Kinlaw AC, Chidgey BA, Cooper T, Delcher C.
Inches, Centimeters, and Yards: Overlooked Denition Choices Inhibit
Interpretation of Morphine Equivalence.




OpioidData.org for code and further details
Nabarun Dasgupta
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Across 4 previously unidentied denitional variants, the following
simple 2 prescription scenario returns daily MME inconsistently:
75.8 or 93.5 or 31.2 or 105 mg/d. We examined how this
fundamental metric impacts population-level inference.
Introduction
A patient receives 30mg extended-release oxycodone twice a day
for around-the-clock pain for 30 days (60 tablets), and
one 5 mg oxycodone twice a day as needed for breakthrough pain
for 7 days (14 tablets). Both prescriptions are dispensed on the
rst day of a 30-day month, with no subsequent dispensing.
Assume 1.5 as the conversion factor oxycodone-to-morphine.
Total MME for the rst prescription:
(60 tablets) × (30 mg per tablet) ×
(1.5 conversion factor from oxycodone-to-morphine),
resulting in 2700 mg.
For the second prescription:
(14 tablets) × (5 mg per tablet) × (1.5 conversion factor),
resulting in 105mg.
Total MME across both prescriptions is 2805 mg, appearing as the
numerator in the rst 3 denitions. 
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